Screener
Alnylam Pharmaceuticals ALNY Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income (loss) from operations | 231,441 | (16,199) | 500,077 | 1,878 |
| Other (expense) income: | ||||
| Interest expense | (82,051) | (61,456) | (151,337) | (119,765) |
| Interest income | 28,143 | 27,486 | 54,741 | 56,159 |
| Other income (expense), net | 273 | 8,860 | (4,022) | 18,051 |
| Total other expense, net | (53,635) | (25,110) | (100,618) | (45,555) |
| Income (loss) before income taxes | 177,806 | (41,309) | 399,459 | (43,677) |
| Provision for income taxes | (13,312) | (30,919) | (28,974) | (46,802) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's interest income?
- Alnylam Pharmaceuticals (ALNY) reported interest income of $28.14M in Q2 2026.
- How has Alnylam Pharmaceuticals's interest income changed year-over-year?
- Alnylam Pharmaceuticals's interest income increased by 2.4% year-over-year, from $27.49M to $28.14M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest income has grown at a 189.9% compound annual growth rate (CAGR), from $1.58M to $111.47M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Alnylam Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude